Ashley McGrane sold $9,239 of GTM
General Counsel and Corp Sec at ZoomInfo Technologies Inc.. 2,461 shares at an average of $3.75, traded Oct 2, 2026, filed Oct 5, 2026.
Score components
- +15RoleOfficer
- 0Trade size$9k at market
- 0Share of holdings soldSold 1.7% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002057389-26-000026, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | MOption exercise Common Stock10b5-1 | +781 | - | - | 107,818 | 9 d ago |
| Oct 1, 2026 | MOption exercise Common Stock10b5-1 | +611 | - | - | 108,429 | 9 d ago |
| Oct 1, 2026 | MOption exercise Common Stock10b5-1 | +552 | - | - | 108,981 | 9 d ago |
| Oct 1, 2026 | MOption exercise Common Stock10b5-1 | +4,468 | - | - | 113,449 | 9 d ago |
| Oct 1, 2026 | MOption exercise Common Stock10b5-1 | +8,375 | - | - | 121,824 | 9 d ago |
| Oct 1, 2026 | MOption exercise Common Stock10b5-1 | +49,219 | - | - | 171,043 | 9 d ago |
| Oct 1, 2026 | FTax withholding Common Stock10b5-1 | -27,913 | $3.79 | $106k | 143,130 | 9 d ago |
| Oct 2, 2026 | SOpen-market sale Common Stock10b5-1 | -2,461 | $3.75 | $9,239 | 140,669 | 9 d ago |
| Oct 1, 2026 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -781 | $0.00 | $0 | 1,563 | 9 d ago |
| Oct 1, 2026 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -611 | $0.00 | $0 | 2,447 | 9 d ago |
| Oct 1, 2026 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -552 | $0.00 | $0 | 3,309 | 9 d ago |
| Oct 1, 2026 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -4,468 | $0.00 | $0 | 26,805 | 9 d ago |
| Oct 1, 2026 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -8,375 | $0.00 | $0 | 50,250 | 9 d ago |
| Oct 1, 2026 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -49,219 | $0.00 | $0 | 295,313 | 9 d ago |
Related signals
Other insiders at ZoomInfo Technologies Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | ZoomInfo Technologies Inc. | James M Roth Chief Revenue Officer | $77k 20,773 shares | -7% | |
| 0Weak | ZoomInfo Technologies Inc. | Ashley McGrane General Counsel and Corp Sec | $142 34 shares | -0% | |
| 0Weak | ZoomInfo Technologies Inc. | James M Roth Chief Revenue Officer | $392 94 shares | -0% | |
| 36Weak | ZoomInfo Technologies Inc. | Ashley McGrane General Counsel and Corp Sec | $68k 16,400 shares | -13% | |
| 10Weak | ZoomInfo Technologies Inc. | Michael Graham O'Brien CFO | $20k 5,000 shares | -2% | |
| 0Weak | ZoomInfo Technologies Inc. | Ashley McGrane General Counsel and Corp Sec | $3,553 997 shares | -1% | |
| 0Weak | ZoomInfo Technologies Inc. | Ashley McGrane General Counsel and Corp Sec | $7,331 2,461 shares | -2% | |
| 0Weak | ZoomInfo Technologies Inc. | James M Roth Chief Revenue Officer | $62k 20,774 shares | -9% | |
| 0Weak | ZoomInfo Technologies Inc. | Ashley McGrane General Counsel and Corp Sec | $121 34 shares | -0% | |
| 0Weak | ZoomInfo Technologies Inc. | James M Roth Chief Revenue Officer | $710 200 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.